Previously, we reported that in a mouse model for Pompe disease, lentiviral gene therapy with LV-GAA or LV-GAAco reduced glycogen levels in most of the tissues, but one of the limitations was that high vector doses were needed and that glycogen was not fully cleared from the major target tissues, especially not from the brain.49 Here, GAA is linked to glycogen storage disease II.